1

2
Mulligan Seamus: Liquid suspension for oral administration.. Elan, December 21, 1988: EP0295941-A2 (19 worldwide citation)

A liquid suspension for oral administration comprises an active ingredient suspended in an edible, non-aqueous carrier vehicle such as an oil, wherein the active ingredient is in the form of controlled release particles containing the active ingredient and optionally an excipient in intimate admixtu ...


3
Mulligan Seamus, Sparks Randall T: Capsule ou comprime a liberation progressive, Sustained release capsule or tablet formulation. Elan Pharma International, KIRBY EADES GALE BAKER, August 27, 1991: CA1288049 (19 worldwide citation)

- 17 - ABSTRACT SUSTAINED RELEASE CAPSULE OR TABLET FORMULATION A sustained release capsule or tablet formulationsuitable for once-daily administration comprises anadsorbate of a mixture of a pharmaceutically usefuldihydropyridine and a polyvinylpyrrolidone having anaverage molecular weight greater ...


4
Foynes Mary Margaret, Geoghegan Edward James, Mulligan Seamus: Pharmaceutical formulations for preventing drug tolerance.. Elan, August 2, 1989: EP0325843-A2 (16 worldwide citation)

Pharmaceutical formulations for once-daily administration of a drug to inhibit the development of drug tolerance in humans being treated with the drug which can achieve therapeutically effective levels of said drug in the plasma over a period of not more than 20 hours of the day and then cause said ...


5
Geoghegan Edward James, Mulligan Seamus, Panoz Donald Eugene: Controlled absorption diltiazem formulations.. Elan, June 14, 1989: EP0320097-A1 (15 worldwide citation)

A controlled absorption diltiazem pellet formulation for oral administration comprises a core of diltiazem or a pharmaceutically acceptable salt thereof in association with an organic acid, and a multi-layer membrane surrounding the core and containing a major proportion of a pharmaceutically accept ...


6
Bourke Edward Anthony, Mulligan Seamus: Enhanced bioavailability adsorbates.. Elan, May 29, 1991: EP0429187-A1 (11 worldwide citation)

An enhanced bioavailability adsorbate formulation comprising an adsorbate of a mixture of a pharmaceutically useful steroid and a polyvinylpyrrolidone adsorbed on a cross-linked polyvinylpyrrolidone.


7
Bourke Edward Anthony, Mulligan Seamus: Controlled absorption naproxen formulation for once-daily administration.. Elan, July 24, 1991: EP0438249-A1 (10 worldwide citation)

A naproxen formulation for oral administration on a once-daily basis comprises a first portion of the naproxen formulated in a multi-particulate pellet form designed to release the drug at a rate sufficient to maintain therapeutically effective blood levels substantially over 24 hours when administe ...


8
Mulligan Seamus, Sparks Randall T: Sustained release capsule or tablet formulation.. Elan, July 13, 1988: EP0274176-A2 (8 worldwide citation)

A sustained release capsule or tablet formulation suitable for once-daily administration comprises an adsorbate of a mixture of a pharmaceutically useful dihydropyridine and a polyvinylpyrrolidone having an average molecular weight greater than 55,000 adsorbed on a cross-linked polyvinylpyrrolidone ...


9
Bourke Edward Anthony, Mulligan Seamus: Formulation de naproxene a liberation controlee pour administration une fois par jour, Controlled absorption naproxen formulation for once-daily administration. Bourke Edward Anthony, Mulligan Seamus, Elan Corporation, KIRBY EADES GALE BAKER, March 26, 2002: CA2034096 (4 worldwide citation)

A naproxen formulation for oral administration on a once-dailybasis comprises a first portion of the naproxen formulated in a multi-particulate pellet form designed to release the drug at a rate sufficient tomaintain therapeutically effective blood levels substantially over 24hours when administered ...


10
Geoghegan Edward James, Mulligan Seamus, Panoz Donald Eugene: Controlled absorption diltiazem formulations. Elan, August 5, 1998: EP0856313-A1 (1 worldwide citation)

A controlled absorption diltiazem pellet formulation for oral administration comprises a core of diltiazem or a pharmaceutically acceptable salt thereof in association with an organic acid, and a multi-layer membrane surrounding the core and containing a major proportion of a pharmaceutically accept ...